EFS for children with ALL continues to increase and is predicted to reach 90% with current therapy. Better understanding of leukemia cell biology and pharmacogenetics has led to the design of more effective treatment and also refined the prognostic features associated with a poor outcome. ALL characterized by the translocation t(9;22) or t(4;11), or by a hypodiploid karyotype or by an incomplete response to induction therapy is likely to relapse. SCT for ALL is largely used to treat patients failing primary chemotherapy but is selectively included as part of initial therapy for children at high risk for relapse. If SCT is going to become the primary therapy for children with ALL in first remission, the regimen-related mortality must approach 0%, and the risk for severe acute and chronic GVHD should be less than 5%. Salvage therapy after ALL relapse remains the major indication for SCT. The time required to find a suitable match has led to the use of cord blood and haploidentical related donors as stem cell sources. For children who relapse, SCT is likely to remain the principal option to promote survival. Efforts to reduce both the risk of relapse and the transplant regimen toxicity, both immediate and delayed, must continue.
Introduction
SCT was developed initially as a salvage therapy for children with advanced ALL.
1,2 Indeed, from this indication came some of the first reports of the successful application of SCT. Then, as now, disease-free survival was superior when patients underwent transplant in remission versus relapse, and leukemic relapse after transplant was the principal cause of failure. It has been proposed that prior chemotherapy-induced resistance in leukemic cells diminished the effectiveness of transplant conditioning therapy. If true, resistance might be avoided by including SCT in the primary treatment design for selected patients. The clinical situation remains much the same today. SCT for ALL is largely used to treat patients failing primary chemotherapy but is selectively included as part of initial therapy for children at high risk for relapse.
SCT in first remission
EFS for children with ALL continues to increase and is predicted to reach 90% with current therapy. 3 Better understanding of leukemia cell biology and pharmacogenetics has led to the design of more effective treatment and also refined the prognostic features associated with a poor outcome. Thus, children whose ALL is characterized by the translocation t(9;22) or t(4;11), or by a hypodiploid karyotype or by an incomplete response to induction therapy are likely to relapse. 3 In a retrospective analysis, children with translocation t(9;22) undergoing SCT from an HLA-identical sibling donor achieved 65% EFS, which is significantly better than the outcome from chemotherapy, 25% EFS. 4 Fewer relapses among the SCT recipients accounted for the improved outcome. More recent prospective multi-institution clinical trials corroborate the advantage of SCT. [5] [6] [7] Retrospective analysis did not find a better outcome for recipients of unrelated or mismatched donor SCT as compared to chemotherapy, largely because of the high TRM. However, the results for alternative donor transplantation as reported in single-center clinical trials have been better, with EFS reaching 50%. At Texas Children's Hospital, for 11 patients with the translocation t(9;22) transplanted from mismatched related or unrelated donors, EFS is 60%. Although the use of alternative donors can be effective for children with the translocation t(9;22), its use as a standard approach is not justified by the current results.
Infant ALL, characterized by MLL gene rearrangement and/ or translocation t(4;11), has historically had a poor outcome, high relapse rate and EFS as low as 19%. 8 More recently, very aggressive chemotherapy regimens have reported 33% EFS but with severe regimen toxicity. 9 Results following SCT, from both related and unrelated donors, find that for infants in first remission, EFS ranges between 64 and 76%. [10] [11] [12] These infants underwent fully ablative conditioning, many receiving TBI, which increases the concern for late effects on growth and neurocognitive development. Although the risk of relapse with chemotherapy is high, it may be proposed to limit SCT to just those infants who relapse. Unfortunately, EFS is poor for infants transplanted after relapse, and it is unlikely to improve especially for patients coming for SCT after extremely aggressive primary chemotherapy. 10, 11 Children with either B-cell or T-cell ALL and specific highrisk features, for example, marked leukocytosis at presentation, hypodiploid karyotype, inadequate response to induction chemotherapy or persistent minimal residual disease, have experienced a high failure rate on contemporary chemotherapy regimens. 3 If an HLA-matched related donor is available, SCT in first remission may be a more effective approach for these very high-risk subsets. The results from studies that attempt to compare EFS after transplant or chemotherapy have been somewhat ambiguous.
7,13-15 EFS for high-risk patients treated by chemotherapy ranged between 40 and 45%. EFS following SCT was comparable to chemotherapy in some reports but better in other reports, EFS 56-67%. These studies attempted to control for potential biases, which arise when randomization is not possible and comparable patient populations must be derived. Unfortunately, no statistical method is entirely satisfactory for this purpose, and it is unlikely that a definitive outcome will come from clinical trials. It is clear that if SCT is going to become the primary therapy for certain children with ALL in first remission, the regimen-related mortality must approach 0% and the risk for severe acute and chronic GVHD should be less than 5%.
SCT after first remission
Salvage therapy after ALL relapse remains the major indication for SCT. Although in the recent past SCT would have been recommended for every child with a sibling donor, newer risk-based strategies have emerged that define the necessity for SCT based upon the site of relapse (BM, central nervous system, other extramedullary) and its timing in relation to completion of primary therapy (early or late relapse). 16 Some investigators recommend chemotherapy alone for patients with isolated central nervous system relapse or late relapse, for example, relapse more than 6 months after completion of primary therapy. Data from the Center for International Blood and Marrow Transplant Research find similar EFS, E60%, for patients who relapse 6 months or more after completion of therapy treated by either chemotherapy or SCT from matched related donor; however, the Berlin-Frankfurt-Munster group reports 44% EFS for similar patients treated by chemotherapy. 16 It is likely that the intensity of the primary therapy influences the response to salvage treatment. For all other children with relapsed ALL, less than one-third will be expected to achieve prolonged EFS with chemotherapy alone. 16, 17 Most reports find a better outcome for children treated with SCT compared to chemotherapy, with EFS ranging from 40 to 60%. 18, 19 Alternative SCT donors Although the indication may be undisputed, a patient cannot undergo SCT without a suitable donor. Over the past several decades, international registries have enlisted millions of volunteers to serve as unrelated stem cell donors for patients in need of transplantation. Currently, in the United States, unrelated donors can be found for more than two-thirds of patients. Unfortunately, the morbidity and mortality that occur during unrelated donor SCT remain substantial. A third or more of patients may die from regimen-related toxicity. 20 Better outcomes are achieved when the transplant staff, particularly nurses, are dedicated and experienced in the care of the transplant patient; unrelated donor SCT should be performed at centers that have gathered significant expertise with this therapy. In such a setting, unrelated donor SCT can be an effective therapy for children with relapse ALL. EFS from 40 to 46% are reported. 11, 21, 22 We have performed SCT from unrelated or mismatched related donors for 39 children with ALL in first or second remission for whom EFS is 55%.
Although the donor registries have increased the number of available donors, the time required to find a suitable match may be too long for some patients. In one report, more than half the patients experienced a second relapse before a donor could be identified. 23 This has led to the use of cord blood and haploidentical related donors as stem cell sources. 24, 25 Reports that compare SCT from cord blood versus BM find less-severe acute GVHD with cord blood even when the donor and recipient are not HLA-identical. 26 Likewise, the technology that permits the selection of a stem cell-enriched product from a haploidentical parent donor permits SCT across a prohibitive immunological barrier. Employing these approaches for patients with acute leukemia in first or second remission or relapse, EFS has ranged from 33 to 60%. 24, 25 As is true for conventional SCT, the patient's disease status at the time of transplant was a major determinant of outcome. For recipients of cord blood, both the cell dose and the degree of HLA match were important to outcome. 24 With the increased availability of cord blood and outcomes comparable to BM SCT, cord blood has gained wide acceptance as a suitable stem cell source for children with ALL needing transplantation.
The future for SCT as treatment for children with ALL will continue to evolve. Further insight into leukemia cell biology will foster improved chemotherapies. The population of children failing primary therapy will hopefully diminish. However, for those children who relapse, SCT is likely to remain the principal option to promote survival. Efforts to reduce both the risk of relapse and the transplant regimen toxicity, both immediate and delayed, must continue.
